Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or peripheral artery disease~* Lp(a) plasma level ≥ 60 mg/dL~* Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD risk factors~Key Exclusion Criteria:~* Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/TIA~* Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis~* Heart failure New York Heart Association (NYHA) class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: ISIS 681257: 20 mg Q4W (Type: EXPERIMENTAL): Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
- Cohort B: ISIS 681257: 40 mg Q4W (Type: EXPERIMENTAL): Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
- Cohort C: ISIS 681257: 60 mg Q4W (Type: EXPERIMENTAL): Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
- Cohort D: ISIS 681257: 20 mg Q2W (Type: EXPERIMENTAL): Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
- Cohort E: ISIS 681257: 20 mg QW (Type: EXPERIMENTAL): Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).

Based on this trial design, predict the completion outcome and termination type (if applicable).